Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
April 27, 2023 07:30 ET
|
Zai Lab Limited
SHANGHAI, China and CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement...
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023 10:25 ET
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that the results of the LUNAR phase 3 clinical trial in metastatic,...
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
April 20, 2023 07:30 ET
|
Zai Lab Limited
SHANGHAI, China and CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of...
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
April 11, 2023 08:03 ET
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data including a translational and biomarker data analysis from its...
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023 06:35 ET
|
Zai Lab Limited
Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well...
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
March 01, 2023 16:01 ET
|
Zai Lab Limited
Total revenue of $215.0 million for 2022, representing a 49.0% increase y-o-y; ZEJULA® achieved 55.2% y-o-y growthStrong balance sheet with a cash position of $1.0 billion as of December 31,...
Zai Lab Announces Participation in March Investor Conferences
February 28, 2023 07:30 ET
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in...
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
February 22, 2023 16:30 ET
|
Zai Lab Limited
SHANGHAI, China and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present two oral presentations highlighting the ad hoc interim overall...
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
February 22, 2023 07:30 ET
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has...
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
February 09, 2023 07:30 ET
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that it will report financial results and corporate updates for the...